Viewing Study NCT00232271



Ignite Creation Date: 2024-05-05 @ 12:03 PM
Last Modification Date: 2024-10-26 @ 9:19 AM
Study NCT ID: NCT00232271
Status: TERMINATED
Last Update Posted: 2013-05-30
First Post: 2005-10-02

Brief Title: The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation
Sponsor: Melbourne Health
Organization: Melbourne Health

Study Overview

Official Title: The Effect of Enoxaparin Sodium Clexane on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation
Status: TERMINATED
Status Verified Date: 2005-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Slow recruitment
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to assess the effect of the anticoagulantblood thinner Clexane on the development of leg clots following electrophysiology studies EPS and or radiofrequency ablation RFA

People who suffer heart palpitations will sometimes need hospital admission to undergo an electrophysiology study and or a Radiofrequency Ablationin order to diagnose and or treat their condition

Radiofrequency ablation is a procedure to stop abnormal heart rhythms EPSRFA studies require the puncture of the leg veins Previous experience has shown that following the puncture of leg veins there is a small risk of developing a blood clot in the leg

It is not known whether giving blood thinners anticoagulants after the procedure will decrease this risk Enoxaparin Sodium Clexane is an anticoagulant used extensively and safely following bone Orthopaedic surgery to prevent blood clots from developing in the legs
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None